Biodistribution of mRNA COVID-19 vaccines in human breast milk - The Lancet
CRAD-B Stock | SEK 30.25 0.65 2.10% |
About 62% of C Rad's investor base is looking to short. The analysis of current outlook of investing in C Rad AB suggests that many traders are alarmed regarding C Rad's prospects. The current market sentiment, together with C Rad's historical and current headlines, can help investors time the market. In addition, many technical investors use C Rad AB stock news signals to limit their universe of possible portfolio assets.
CRAD-B |
Biodistribution of mRNA COVID-19 vaccines in human breast milk The Lancet
Read at news.google.com
C Rad Fundamental Analysis
We analyze C Rad's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of C Rad using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of C Rad based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
C Rad is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
C Rad AB Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with C Rad stock to make a market-neutral strategy. Peer analysis of C Rad could also be used in its relative valuation, which is a method of valuing C Rad by comparing valuation metrics with similar companies.
Peers
C Rad Related Equities
CEVI | CellaVision | 2.96 | ||||
BIOT | Biotage AB | 0.12 | ||||
RAY-B | RaySearch Laboratories | 0.99 | ||||
BONEX | Bonesupport Holding | 1.26 | ||||
BOUL | Boule Diagnostics | 3.97 |
Complementary Tools for CRAD-B Stock analysis
When running C Rad's price analysis, check to measure C Rad's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C Rad is operating at the current time. Most of C Rad's value examination focuses on studying past and present price action to predict the probability of C Rad's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C Rad's price. Additionally, you may evaluate how the addition of C Rad to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |